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Abstract
Background: Increases in human telomerase reverse transcriptase (TERT) expression and telomerase activity are
frequently seen in nasopharyngeal carcinoma (NPC). Recently, a variable tandem-repeats polymorphism, MNS16A,
located in the downstream region of the TERT gene, was identified and reported to have an effect on TERT
expression and telomerase activity. We examined whether the functional MNS16A was related to the risk of
occurrence or progression of NPC in the Chinese population.
Methods: We genotyped the MNS16A polymorphism in a case-control study of 855 patients with NPC and 1036
cancer-free controls using PCR, and determined genotype by classifying the DNA band of 243 or 272 base pairs
(bp) as the short (S) allele and 302 or 333 bp as the long (L) allele. The genetic associations with the risk of NPC
were analyzed by logistic regression.
Results: The MNS16A genotype was not associated with the progression of NPC. However, individuals carrying the
S alleles (SL + SS genotype) had a significantly reduced risk of NPC occurrence compared with those carrying the
LL genotype (odds ratio (OR) = 0. 71, 95% confidence interval (CI) = 0. 52 to 0. 96, P = 0. 025). Using a
immunohistochemical assay on the NPC tissues, the SL genotype carriers were found to have lower TERT
expression than the LL genotype carriers (P = 0. 035).
Conclusions: Our study indicates that the TERT MNS16A polymorphism may contribute to the risk of NPC onset in
Chinese population.
Background
Nasopharyngeal carcinoma (NPC) is an epithelial malig-
nancy with strikingly variable racial and geographic dis-
tribution. It is particularly prevalent in populations from
southeast Asia, with an incidence rate ranging from 15
to 50 per 100,000, which is ~100 times higher than that
in Caucasian populations [1]. Like other kinds of cancer,
the risk of NPC is influenced by both genetic and envir-
onmental risk factors. Epstein-Barr virus (EBV) infection
has a crucial role in the pathogenesis of NPC. Numer-
ous environmental risk factors, including long-term
cigarette smoking, occupational formaldehyde exposure
and various dietary factors, have been reported to confer
a risk of developing NPC [2]. In addition, numerous
genetic linkage and association studies have reported a
few genes contributing to ther i s ko ft h i sm a l i g n a n c y
[3-6]. The identification of susceptibility genes contri-
buting to NPC may help to clarify the pathogenesis of
carcinogenesis, and improve the prevention and treat-
ment of this malignancy.
Telomeres are structures that cap the distal ends of
chromosomes, and function to prevent chromosome
degradation, end-to-end fusions, rearrangements and
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instability is a widespread cause of genome instability in
cancer, and is thought to be the crucial event in tumori-
genesis [7]. Telomerase is a reverse transcriptase enzyme
that can elongate the TTAGGG repeats of telomeres in
cells, in which it is expressed to maintain the ends of
chromosomes and sustain cellular immortality. Telomer-
ase is a holoenzyme, and its catalytic subunit (telomer-
ase reverse transcriptase, TERT) is the core component
responsible for its enzymatic activity [8]. In humans, tel-
omerase activity is undetectable in most normal cells,
with the exception of peripheral and cord blood, and
bone marrow leukocytes [9]. The existence of detectable
telomerase expression in almost all types of human can-
cers suggests that enhanced telomerase expression is
crucial for cell growth during tumorigenesis [10-12].
With regard to NPC, increased telomerase activity and
TERT expression is also common in tumor tissues, and
can be detected at high frequencies compared with nor-
mal nasopharyngeal epithelium and tissues [12,13]. It
has been shown that normal nasopharyngeal epithelial
cells can be transformed into immortalized cells by acti-
vating telomerase [14]. By contrast, small hairpin (sh)
RNA directed against TERT inhibits cell viability by reg-
ulating telomerase activity and its related protein
expression in NPC cells [15]. Additionally, latent mem-
brane protein (LMP)1, which is the principal oncopro-
tein encoded by EBV, was able to induce the direct
binding of TERT to nuclear factor kappa B (NF-B) p65
in NPC cells, then lead to translocation of both proteins
from the cytoplasm to the nucleus, and subsequent acti-
vation of telomerase and cell immortalization [16].
Another study found that small interfering (si)RNA tar-
geting LMP1 can induce apoptosis in EBV-positive lym-
phoma cells, and is associated with inhibition of
telomerase activity and expression [17]. Furthermore,
with regard to the clinicopathological features in
patients with NPC, telomerase activity was seen more
frequently in the advanced clinical stages (III to IV) and
in patients with lymph-node metastasis (N1 to N3)
[18,19]. Taken together, these observations indicate that
telomerase and TERT play an important role in the
occurrence and progression of NPC [20].
Based on the functional relevance of TERT in the
pathogenesis of NPC described above, we hypothesized
that the TERT might be an excellent biological candi-
date susceptibility gene for NPC, and that functional
polymorphisms within TERT m i g h tr e s u l ti ng e n o t y p e -
dependent differences in susceptibility to NPC.
In a previous study, a functional variable number of
tandem repeats (VNTR) polymorphism, MNS16A, was
identified in the downstream region of the TERT gene
on chromosome 5p15. 33 [21]. The region containing
MNS16A was found to have some promoter activity
that was influenced by the length of the MNS16A tan-
dem repeats, suggesting a potential role of this minisa-
tellite in regulating both the expression of the antisense
TERT mRNA level and the activity of telomerase [21].
Therefore, we hypothesized that this functional poly-
morphism in the downstream of TERT gene might con-
tribute to the tumor susceptibility. Indeed, several
genetic epidemiological studies have shown MNS16A to
be a potential risk factor and/or a prognostic marker of
lung [21-23], breast [24], brain [25-27] and colorectal
[28] cancers. However, the role of MNS16A in NPC has
never been specifically investigated. In this study, we
examined whether the functional polymorphism in the
downstream region of TERT, MNS16A, has any bearing
on the occurrence or progression of NPC in the Chinese
population.
Methods
Ethics
The study was approved by the ethics committee of
Beijing Institute of Radiation Medicine (Beijing, China),
and written informed consent was obtained from all the
participants involved.
Study population
This case-control study enrolled 855 patients with inci-
dent NPC and 1036 control subjects (see Additional file
1, Table S1). All subjects were unrelated ethnic Chinese
adults, who were resident in Nanning City (Nanning,
China) and the surrounding regions. At recruitment,
personal information on demographic factors, medical
history, and tobacco and alcohol use were collected via
a structured questionnaire.
Diagnosis of patients and the inclusion and exclusion
criteria for patients and controls have been described in
detail previously [29]. Briefly, all patients were consecu-
tively recruited between September 2003 and January
2008 at the Guangxi Cancer Hospital (Nanning, China)
in Guangxi province, a well-known high-risk region for
NPC located in southern China. The response rate for
the patients was 95%.
The inclusion criterion for patients with NPC was that
their diagnosis pf NPC had been histopathologically
confirmed. Patients who had received chemotherapy or
radiotherapy before undergoing surgery or had other
type of cancer were excluded from this study. Tumor
staging was performed according to the tumor, node,
metastasis (TNM) classification of the 1997 American
Joint Committee on Cancer (AJCC) system. All TNM
classifications were determined by senior pathologists of
the hospital, on the basis of the postoperative histo-
pathologic examination. All the controls were recruited
in the same regions during the same time that the NPC
cases were collected. The selection criteria for the
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frequency matching to the cases on gender and age (± 5
years). The response rate for the controls was 96%.
From the group of 855 patients with incident NPC, 41
patients who had undergone resection before receiving
any further treatment at Guangxi Cancer Hospital were
selected, and primary NPC biopsies were collected from
them (see Additional file 1, Table S2). The histological
type of all tumor tissues was poorly differentiated squa-
mous cell carcinoma (SCC). Histological non-cancerous
nasopharyngeal epithelium tissues were collected from
13 of the 1036 control subjects (see Additional file 1,
Table S2). All the tissues were fixed in paraformalde-
hyde, embedded in paraffin wax, and prepared for
immunohistochemical (IHC) staining.
Polymorphism genotyping
The MNS16A polymorphism was genotyped by PCR with
the primers described previously [21] (forward primer: 5’-
AGGATTCTGATCTCTGAAGGGTG-3’, located at
nucleotide (nt) 22591; reverse primer: 5’-TCTGCCTGAG-
GAAGGACGTATG-3’, located at nt 22871. GenBank:
AF128894. 1). Briefly, PCR was performed in a total
volume of 15 μl with an initial denaturing step for 5 min-
utes at 95°C, followed by 43 cycles of 30 seconds at 95°C,
45 seconds at 61°C and 1 minutes at 72°C, and a final
extension step with 10 minutes at 72°C. The PCR products
were separated in a 2. 5% agarose gel, visualized with UV
light, and photographed. Four lengths of repeat poly-
morphisms were seen: 243, 272, 302 and 333 bp. As
reported previously [24], we also saw one extra band for
every heterozygous genotype, which resulted from a con-
formational change of the PCR products with different
allele lengths. However, when the denatured PCR products
from every heterozygous subject were separated in an 8%
denatured polyacrylamide gel, the extra band disappeared
(see Additional file 1, Figure S1).
For further quality control, a new set of primer pairs
was designed to validate the above genotypes (forward
primer: 5’-AAAGTCACATTCCGCCTCTG-3’’ located at
nt 22549; reverse primer:5’-TCTGCAATCCTTC-
CAGTTCC-3’, located at nt 22894. GenBank: AF128894.
1). PCR was performed in a total volume of 15 μlw i t h
an initial denaturing step for 5 minutes at 95°C, fol-
lowed by 35 cycles of 30 seconds at 95°C, 45 seconds at
52°C and 1 minute at 72°C, and a final extension step of
10 minutes at 72°C. Using the new primers, four lengths
of repeats polymorphism were also seen: 306, 335, 365
and 396 bp, corresponding to the previously seen bands
of 243, 272, 302 and 333 bp, respectively. One extra
band for every heterozygous genotype was still visible in
a 2. 5% agarose gel and disappeared in an 8% denatured
polyacrylamide gel (see Additional file 1, Figure S2). A
masked, random sample of 15% of the cases and
controls was tested with the new primers, and all results
had 100% concordance. Genotyping was performed by
staff blinded to the subjects’ status (case or control).
IHC staining analysis
NPC tissues (n = 41) and non-tumor nasopharyngeal
tissues (n = 13), which had been fixed with paraformal-
dehyde and embedded in paraffin wax, were analyzed
for protein expression of TERT. Two slides from each
biopsy were stained with hematoxylin and eosin for rou-
tine histological evaluation. The slides were washed in
xylene to remove the paraffin wax, and then rehydrated
through serial dilutions of alcohol, followed by washing
in phosphate-buffered saline (PBS) pH 7. 2. All subse-
quent washes were buffered via the same protocol. The
slides were then incubated with 3% H2O2 for 10 minutes
to reduce non-specific staining. Treated slides were
placed in citrate buffer pH 6. 0, and heated in a pressure
cooker for 2 minutes. The slides were then incubated
for overnight at 4°C with rabbit anti-human TERT
monoclonal antiboby (LS-C49516; Lifespan, Seattle, WA
and USA.). After washing, the slides were treated with a
commercial kit (MaxVision™ HRP-Polymer Anti-Rabbit
Immunohistochemistry Kit; Maxim Co., China). All
slides were then incubated with 3,3-diaminobenzidine
tetrahydrochloride (DAB), and the cells were counter-
stained with hematoxylin. Negative and positive controls
were performed at the same time. The slides were
mounted with neutral balsam for examination. Photo-
graphs were taken (BX51 microscopic/Digital Camera
System; Olympus) for study comparison.
The IHC signals were scored as previously described
[30]. Briefly, a proportion score was assigned, represent-
ing the estimated proportion of positively staining
tumor cells (0 = none, 1 = < 1% of cells, 2 = 1% to <
10%, 3 = 1% to 33%, 4 = 33% to 66%, 5 = > 66%). Aver-
age estimated intensity of staining in positive cells was
assigned an intensity score (0 = none, 1 = weak, 2 =
intermediate, 3 = strong). The two parameters were
combined, resulting in an overall score (0 or 2 to 8).
The scores were classified into three groups: group 1
were slides with a score of 0 (negative expression),
group 2 were those scoring 2 to 4 (low expression) and
group 3 were those scoring > 5 (high expression). A
total of five fields per slide were selected, counted and
averaged. Slides were scored by two pathologists (JHW
a n dA C W )w h ow e r eb l i n d e dt ot h el i g a n d - b i n d i n g
assay results or patient outcome. Consistent with a pre-
vious report [31], TERT was found to locate in the
nucleus and cytoplasm of cancer cells.
Statistical analysis
The c
2 test was used to compare gender, ethnicity,
tobacco and alcohol use, and family history of first-
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unpaired t-test was used to analyze differences in mean
age and mean smoking level between patients and
controls.
Genotype and allele frequencies for the MNS16A
polymorphism were determined by gene counting, and
departures from Hardy-Weinberg equilibrium were
tested using the random-permutation procedure imple-
mented in the Arlequin package [32]. The association
between the genotypes and NPC risk was evaluated by
multivariate logistic regression analyses. The odds ratio
(OR) and 95% confidence interval (CI) were adjusted for
age, gender, tobacco and alcohol use, smoking level, eth-
nicity and family history where appropriate. Potential
modification of the effect of MNS16A genotypes on the
risk and progression of NPC was assessed for the above
confounding factors by addition of interaction terms in
the logistic model, and by separate analyses of sub-
groups of subjects determined by these factors. To
assess the probability of a spurious association due to
multiple testing, we calculated the false-positive report
probability (FPRP) for a polymorphism from an esti-
mated OR and 95% CI, using the method described by
Wacholder et al [33]. FPRP of < 0. 5 was considered to
indicate a robust association.
Differences in the protein levels detected by IHC
between the tumor and non-tumor tissue, and between
the MNS16A L and S allele carriers were assessed by a
Wilcoxon signed-ranks test and a trend c
2 test, respec-
tively. Logistic regression analysis was also performed
for MNS16A genotypes, with the IHC staining scores as
the outcome variable.
P < 0. 05 was considered significant, and all statistical
tests were two-sided. These analyses were performed
using SPSS software (version 17. 0, SPSS Inc., Chicago,
IL, USA).
Results
The selected demographic and clinical characteristics of
patients with NPC and control subjects were described
in detail previously (see Additional file 1, Table S1) [29].
Briefly, the patients were comparable with controls with
regard to gender and status of tobacco and alcohol.
However, cases were more likely than controls to have
an older mean age (P = 0. 0011, t-test), positive history
of NPC in their first-degree biological relatives (c
2 = 15.
96, P =6 .5×1 0
-5) and non-Han ethnicity (c
2 = 58. 07,
P =2 .5×1 0
-14). An absolute majority of cases (97. 0%)
was classified as having poorly differentiated SCC.
According to the TNM system, 4. 8%, 46. 2%, 30. 3%
and 18. 7% of patients had stage I, II, III and IV disease,
respectively.
The genotyping results are shown in Table 1. This
case-control study included 855 patients with incident
NPC and 1036 control subjects. However, there was fail-
ure of 74 samples (57 cases and 17 controls) in the gen-
otyping assay due to DNA quality and/or quantity.
Therefore, 798 cases (93. 4%) and 1019 controls (98.
3%) were included in the final analysis for the MNS16A
polymorphism. We identified four alleles, of sizs 243,
272, 302 and 333 bp. Only one patient with NPC had
the 333 bp allele, and to our knowledge, this is the first
report of this allele. Compared with the common 302
bp allele, the short alleles (243 and 272 bp) were not
found to be associated with the risk of NPC (all P >0 .
05; Table 1). We identified six genotypes in our case-
control population of Chinese ancestry (see Additional
file 1, Figure S1 and S2, lanes 1 to 6) rather than the
seven reported for non-Hispanic whites [25]. The
observed genotype frequencies for the MNS16A variant
were in Hardy-Weinberg equilibrium (HWE) in both
cases (P = 0. 58) and controls (P = 0. 17). When the
commonest genotype (that is, 302/302) was designated
as reference group, all the other genotypes were still not
associated with the risk of NPC (all P > 0. 05; Table 1).
In accordance with a previous report [21], the 243 bp
and 272 bp bands were classified as the short (S) allele,
and the 333 bp and 302 bp were classified as the long
(L) allele. The MNS16A genotypes were therefore
defined as LL, SL and SS. The frequencies of the LL, SL
and SS genotype were significantly different for cases
and controls (c
2 = 6. 06, P = 0. 048, degree of freedom
(df) = 2), and this difference was mainly caused by the
lower frequencies of the SL and SS genotype in the case
group compared with the control group. Based on logis-
tic regression analysis with adjustment for age, gender,
tobacco and alcohol use, ethnicity, and family history of
NPC, individuals carrying the S alleles (SL + SS geno-
type) had a significantly reduced risk of NPC occurrence
compared with those carrying the LL genotype (OR = 0.
71, 95% CI = 0. 52 to 0. 96, P = 0. 025). This association
remained robust given prior probabilities of actual asso-
ciation of 25% (FPRP = 0. 13) and 10% (FPRP = 0. 30),
but not with a prior probability of 1% (FPRP = 0. 83)
[33]. When cases were limited to those with poorly dif-
ferentiated SCC who were successfully genotyped (n =
773), the significant association results were more evi-
dent (OR = 0. 67, 95% CI = 0. 50 to 0. 90, P = 0. 0068).
The association between the MNS16A and risk of NPC
occurrence were further examined with stratification by
age, gender, tobacco and alcohol use, smoking level, eth-
nicity, and family history (Table 2). Although the
decreased risk of NPC associated with the MNS16A SL
+ SS genotypes was more pronounced in subjects who
were older (≥ 45 years), male, smokers, drinkers, Han
Chinese and with a negative family history, these differ-
ences could be attributed to chance (all P >0 .0 5 ,t e s t
for homogeneity), indicating that these potential
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risk of NPC related to MNS16A genotypes.
Furthermore, we evaluated the effect of the MNS16A
SL + SS genotypes on severity of NPC (as measured by
the TNM staging system). However, the distributions of
the MNS16A genotypes were not significantly different
between subgroups with different clinical stages or dif-
ferent TNM classifications (all P > 0. 05; Table 3).
In 798 patients with NPC in the Guangxi population,
the mean ± SD age at diagnosis was 46. 75 ± 11. 82
years for subjects with the LL genotype and 47. 78 ± 13.
58 years for those with the SL or SS genotype. There-
fore, subjects carrying with the protective S allele were
on average 1. 03 years older at diagnosis than those
with the LL genotype, although the difference was not
significant (P = 0. 33, t-test).
We further investigated the protein expression of
TERT in NPC tissues and non-cancerous nasopharyn-
geal epithelium tissues by IHC assay (Table 4; see Addi-
tional file 1, Table S3). We detected positive expression
of TERT in the 34 of 41 NPC tissues (82. 9%), but nega-
tive expression in all 13 non-cancerous nasopharyngeal
tissues. Furthermore, there was significant association
between MNS16A genotypes and expression of TERT in
the NPC tissues, with the SL genotype carriers having
lower TERT expression than the LL genotype carriers (P
= 0. 032, logistic regression analysis; c
2 =6 .6 7 6 ,P =0 .
035).
Discussion
In this study, we assessed the associations of the func-
tional VNTR downstream of the TERT gene MNS16A
with the risk of occurrence and progression of NPC in
the Guangxi population in southern China. No genetic
association was found between this polymorphism and
the progression of NPC. However, this polymorphism
was significantly associated with the onset of NPC, espe-
cially in poorly differentiated SCC. This is the first
report, to our knowledge, of the genetic association
between the TERT MNS16A and risk of NPC, confirm-
ing the initial hypothesis that the TERT may play a role
in the pathogenesis of this malignancy.
In our study population, the S allele (SL + SS geno-
type) was over-represented in controls compared with
cases. Furthermore, carriers of the S alleles tended to
have an older age of diagnosis than those of the LL gen-
otype, suggesting a protective role of the MNS16A S
allele against the onset of NPC. It was reported that the
region containing MNS16A had some promoter activity
that was influenced by the length of the MNS16A tan-
dem-repeats polymorphism [21]. The MNS16A S allele,
compared with the L allele, was associated with higher
Table 1 The genotype and allele frequencies of MNS16A in patients with nasopharyngeal carcinoma and cancer-free
controls
MNS16A
a Cases, n (%), n = 798
b Controls, n (%), n = 1019
b OR (95% CI)
c,d P
c
Alleles, bp
302 (reference) 1520 (95. 2) 1903 (93. 4) 1. 00
243 44 (2. 8) 76 (3. 7) 0. 74 (0. 51 to 1. 08) 0. 12
272 31 (1. 9) 59 (2. 9) 0. 65 (0. 42 to 1. 01) 0. 058
333 1 (0. 06) 0 - -
Genotypes
302/302 (reference) 724 (90. 7) 891 (87. 4) 1. 00
243/302 41 (5. 2) 65 (6. 4) 0. 80 (0. 53 to 1. 20) 0. 29
272/302 30 (3. 8) 56 (5. 5) 0. 64 (0. 41 to 1. 01) 0. 059
243/243 1 (0. 1) 4 (0. 4) 0. 36 (0. 04 to 3. 73) 0. 41
243/272 1 (0. 1) 3 (0. 3) 0. 33 (0. 04 to 2. 94) 0. 32
302/333 1 (0. 1) 0 - -
Group of genotypes
LL (reference) 725 (90. 9) 891 (87. 4) 1. 00
SL 71 (8. 9) 121 (11. 9) 0. 73 (0. 53 to 0. 99) 0. 037
SS 2 (0. 2) 7 (0. 7) 0. 35 (0. 07 to 1. 69) 0. 17
SL + SS 73 (9. 1) 128 (12. 6) 0. 71 (0. 52 to 0. 96) 0. 025
Group of alleles
L (reference) 1521 (95. 0) 1903 (93. 0) 1. 00
S 75 (5. 0) 135 (7. 0) 0. 86 (0. 78 to 0. 96) 0. 014
aOwing to genotyping failure, the actual sample size was 798 and 1019 for the cases and controls, respectively.
bL allele was 302 or 333 bp; S allele was 243 or 272 bp.
cThe odds ratios (ORs) and P values were adjusted for age, gender, tobacco and alcohol use, smoking level, ethnicity and family history.
dConfidence interval.
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our study, we further investigated the protein expression
of TERT in NPC and non-cancerous nasopharyngeal
epithelium tissues by IHC. We found that the SL geno-
type was significantly associated with lower TERT
expression than the LL genotype (Table 4). Given the
role of TERT in the development of NPC, it might be
expected that people who carry the MNS16A S allele,
and thus have more antisense TERT RNA and lower
TERT protein expression (and thereby lower telomerase
activity) over a lifetime, would have a lower susceptibil-
ity to developing this disorder. However, the exact func-
tional molecular mechanisms of MNS16A remain
unknown. Further studies will be needed to clarify how
MNS16A affects antisense RNA transcription and how
antisense RNA affects TERT expression.
Recently, the TERT MNS16A has been studied in many
cancers, but the results are conflicting. Consistent with
this study in NPC, one study reported an association of
the MNS16A S allele with a decreased risk of non-small-
cell lung cancer (NSCLC) [21]. By contrast, a very recent
study found no association between MNS16A and risk of
glioma, glioblastoma and meningioma [27], and some
reports have shown a reverse association with the risk
allele, with the MNS16A S allele conferring an increased
risk of breast cancer, glioblastoma and anaplastic glio-
mas [24,26]. Recently, some reports have questioned the
validity of the S and L combining system, and assessed
directly the association of the raw alleles with the dis-
eases. For example, Jin et al. found that the 243 bp
allele, but not the 272 bp allele, was associated with the
risk of lung cancer in a Korean population [23]. Hofer
et al. reported that only the 274 bp allele was associated
with the risk of colorectal cancer [28]. In this study we
found that both the 243 bp and 272 bp alleles were not
associated with the risk of NPC. These conflicting
results could be attributable to the different ethnicities
of study populations and/or different tumorigenesis of
different cancers. Additionally, other factors in the stu-
dies, such as small sample size or inadequate adjust-
ment for confounding factors, could also cause the
inconsistent results. Consequently, additional well-
designed case-control studies on a wide spectrum of
cancers with ethnically diverse populations are war-
ranted to understand the roles of the MNS16A poly-
morphism in the etiology of cancers.
Table 2 Risk of nasopharyngeal carcinoma associated with MNS16A by potential risk factors
Category LL
a,b SL + SS
a,b OR (95% CI)
c,d P
e Phomogeneity
f
Age, years 0. 55
< 45 331/448 34/60 0. 78 (0. 50 to 1. 22) 0. 19
≥ 45 394/438 39/68 0. 65 (0. 43 to 0. 98) 0. 051
Gender 0. 24
Male 525/646 44/88 0. 61 (0. 42 to 0. 90) 0. 0090
Female 200/245 29/40 0. 90 (0. 54 to 1. 51) 0. 61
Tobacco use 0. 11
Nonsmoker 502/624 56/85 0. 82 (0. 57 to 1. 18) 0. 28
Smoker 223/267 17/43 0. 47 (0. 26 to 0. 85) 0. 0090
Smoking level (pack-years) 0. 34
< 24 635/787 65/109 0. 74 (0. 53 to 1. 03) 0. 071
≥ 24 90/104 8/19 0. 47 (0. 20 to 1. 13) 0. 080
Alcohol use 0. 39
Non-drinker 509/630 55/89 0. 76 (0. 53 to 1. 09) 0. 13
Drinker 217/261 18/39 0. 56 (0. 31 to 1. 02) 0. 032
Ethnicity 0. 77
Han 541/776 57/112 0. 72 (0. 52 to 1. 02) 0. 064
Non-Han 184/115 16/16 0. 67 (0. 30 to 1. 50) 0. 67
Family history
f 0. 70
Negative 678/862 71/127 0. 69 (0. 51 to 0. 95) 0. 022
Positive 47/29 2/1 1. 12 (0. 09 to 13. 26) 0. 88
aOwing to genotyping failure, the actual sample size was 798 and 1019 for the cases and controls, respectively.
bNumber of genotype in cases/number of genotype in controls. L allele, 302 or 333 bp; S allele, 243 or 272 bp.
cThe odds ratios (ORs) and P values were calculated by logistic regression with LL genotype as the reference group and adjusted for age, gender, tobacco and
alcohol status, smoking level, ethnicity and family history where appropriate within the strata.
dConfidence interval
eFor difference in ORs within each stratum.
fFirst-degree relatives
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MNS16A polymorphism in populations from other stu-
dies based on available published data to identify differ-
ences from our own study. We found that the
frequencies of the SS, SL and LL genotype in our con-
trols were 0. 2%, 8. 9% and 90. 9% (Table 1), respec-
tively, similar to those of a Nanjing population of
Chinese descent (0. 4%, 9. 8% and 89. 8% in controls,
respectively) [24] and a Korean population (0. 2%, 10.
7% and 89. 1% in controls, respectively) [23] described
previously. We also found that the frequencies of the
MNS16A genotypes were similar for controls of Cauca-
sian descent from America, France, Austria, the UK and
Nordic countries, with the SS, SL and LL genotype fre-
quencies being 9. 2 to 13. 9%, 40. 3 to 47. 2% and 43. 6
to 47. 8%, respectively [21,26-28]. Obviously, the fre-
quencies of the MNS16A genotypes were significantly
different from those of populations of Chinese descent
(P < 0. 05, c
2 test). It remains to be determined whether
these differences between ethnic groups influence the
risk of developing NPC.
Previous studies have also reported that the TERT
MNS16A polymorphism was associated with clinical
progression in some types of cancer, including clinical
stage, tumor stage, lymph-node metastasis and survival
time, although the results were contradictory. Wang et
al. observed a significantly prolonged survival time for
patients with glioblastoma with the SS genotype com-
pared with the SL or LL genotype [25]. However, this
finding contradicted those from other studies, in which
the LL genotype was significantly associated with longer
survival time in patients with glioblastoma [27] and
early-stage (I or II) NSCLC [22], and was associated
with decreased risk of axillary lymph-node metastasis in
patients with breast cancer [24]. It is also discrepant
with the study by Carpentier et al., which did not find
any survival differences for patients with glioblastoma or
anaplastic glioma with different MNS16A genotypes
[26]. In patients with NPC, increased telomerase activity
and TERT expression was seen more frequently in
patients with advanced clinical stage (III to IV) and
lymph-node metastasis (N1 to N3) [18,19]. However, in
the present study, we did not find any significant asso-
ciations between the MNS16A polymorphism and the
pathological stages of NPC (Table 3). These findings
may be due to the different molecular mechanisms of
carcinogenesis in different cancers and/or to the differ-
ent ethnicities of study populations. In addition, these
findings could be the result of the limited sample size
and statistical power of our study. For example, this
study has only a power of 28. 1% (I + II vs. III + IV),
21. 7% (T1 + T2 vs. T3 + T4), 22. 0% (N0 + N1 vs. N2
+ N3) and 3. 8% (M0 vs. M1) to detect an OR of 0. 70
for carriers of the SL + SS genotypes relative to the
Table 3 Distributions of genotypes of the MNS16A
between the subgroups of cases
a with different
progression of nasopharyngeal carcinoma (NPC)
NPC stage LL
b n (%) SL + SS
b, n (%) c
2c P
Clinical
I 36 (90. 0) 2 (10. 0) 1. 554 0. 21
II 334 (89. 8) 38 (10. 2)
III 212 (90. 2) 23 (9. 8)
IV 143 (93. 5) 10 (6. 5)
Tumor (T) 3. 314 0. 069
T1 151 (91. 5) 14 (8. 5)
T2 356 (89. 9) 40 (10. 1)
T3 139 (89. 7) 16 (10. 3)
T4 79 (96. 3) 3 (3. 7)
Node(N) 0. 667 0. 41
N0 148 (89. 2) 18 (10. 8)
N1 350 (91. 1) 34 (8. 9)
N2 156 (90. 7) 16 (9. 3)
N3 71 (93. 4) 5 (6. 6)
Metastasis(M) 0. 000 1. 00
M0 708 (90. 9) 71 (9. 1)
M1 17 (89. 5) 2 (10. 5)
aOwing to genotyping failure, the actual sample size of the cases was 798.
bL allele, 302 or 333 bp; S allele, 243 or 272 bp.
cComparisons of genotype distributions between the different subgroups
were performed using the c
2 test. The degrees of freedom for the clinical, T
and N stages is 3, and for the M stage is 1
Table 4 Correlation between protein expression levels of
telomerase reverse transcriptase (TERT) and MNS16A
genotypes by immunohistochemistry
Tissues Genotypes
a Expression levels,
bn P
c
Negative Low High NPC vs.
non-NPC
LL vs.
SL +
SS
NPC
d
tissues
4. 78 × 10
-
7
0. 035
LL 51 1 2 1
SL 22 0
SS 00 0
Non-
cancer
e
NA
f
LL 11 0 0
SL 10 0
SS 10 0
aL allele, 302 or 333 bp; S allele, 243 or 272 bp.
bExpression levels were classified into three groups (negative, low and high
expression) based on the scores of the immunohistochemistry signals.
cThe difference of the TERT protein level between the genotypes was
assessed by a trend c
2 test. The difference of the protein level between the
tumors and non-cancerous nasopharyngeal tissues was assessed by a
Wilcoxon signed-ranks test.
dNasopharyngeal cancer
eNon-cancerous nasopharyngeal tissues
fNot available.
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Page 7 of 9carriers of the LL genotype. Therefore, we urge that the
role of the MNS16A in the progression of NPC be
investigated in additional studies with larger sample
sizes.
Recently, numerous genome-wide association studies
(GWAS) have been carried out to identify associations
between cancer risk and single-nucleotide polymorph-
isms (SNPs). Multiple independent GWAS have all
shown the TERT-CLPTM1L locus on 5p15. 33 to be sig-
nificantly associated with many different types of cancer,
including basal cell carcinoma, glioma, lung, prostate,
bladder, testicular germ cell, pancreatic, and cervical
cancers [34]. Thus, the evidence that the TERT locus
contains risk factors for cancer is compelling. Further
studies are needed to systematically verify the SNPs at
the TERT locus, investigate the interactions between
these SNPs and MNS16A, and and assess their contri-
butions to the endemics of NPC in the Chinese
population.
In reviewing the results of this study, several potential
limitations should be kept in mind. First, as this was a hos-
pital-based study, our NPC cases were enroled from the
hospitals, and the controls were selected from the commu-
nity population, thus inherent selection bias cannot be
completely excluded. However, through further adjust-
ment and stratification in data analyses, we aimed to mini-
mize the potential confounding effect. Second, several
association studies have reported identification of the
genes that may relate to the susceptibility to NPC [35-39];
however, most of the results could not be replicated in
subsequent studies in other populations. Although we
found a significant association between MNS16A and risk
of NPC, our initial findings should be independently veri-
fied in other populations with a high incidence rate of
NPC, such as other southern Chinese, Taiwanese and Sin-
gaporeans. Without rigorous replication we cannot
exclude the possibility that these findings are due only to
chance. Therefore, any association reported in the present
study should be interpreted with great caution.
Conclusions
Our results reveal an association for the first time
between the functional tandem repeat polymorphism
MNS16A downstream of TERT and susceptibility to
NPC. Furthermore, the S allele, which is associated with
higher expression of the TERT antisense RNA and lower
expression of the TERT protein, seems to be a genetic
protection factor for NPC risk in a Chinese population. If
confirmed by other studies, knowledge of genetic factors
contributing to the pathogenesis of the NPC as presented
here may have implications for the cancer screening and
treatment of this disorder in the future.
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